Generic entry is inevitable—unless you build a moat that can’t be copied.
Most pharma conversations fixate on patents that cover what a drug is. But the real battlefield is often how it’s made. Process patents—those that protect the manufacturing met…

Biotech investing can feel like a high-wire act—until you realize the real risk isn’t just clinical failure. It’s patent failure.
A promising Phase 2 readout, a compelling platform, and a clean balance sheet can still collapse if the IP foundation is s…

Biosimilar entry windows aren’t “just spreadsheets.” They’re strategy under pressure.
In the biosimilar market, timing is everything—yet many companies still treat entry-window modeling like a back-office exercise. That’s where costly mistakes begin….

Before You File: The Hidden Cost of Guessing in Generic & Biosimilar Development
In generic and biosimilar development, the most expensive decision is often the one made too early—before you’ve mapped the patent landscape with enough rigor to know …

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the real fight often isn’t over the “main” patent. It’s over what comes after—secondary formulation patents that can quietly exten…

Your pharmaceutical portfolio has a time bomb in it. Patent expiration data tells you where.
If you’re building a pipeline, you already know the obvious risks: clinical failure, enrollment delays, manufacturing scale-up, payer pushback. But there’s a q…

The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/

Big Pharma’s IP strategy is often sold like a fortress: layered patents, procedural maneuvers, and a narrative that “the science is protected.” But in the real world, the wall isn’t always as solid as it looks—because patents are documents, not vibes.
…

Brands don’t “lose” to authorized generics—they design the loss.
That’s the counterintuitive takeaway from the authorized generic playbook: when a brand launches an authorized generic (AG), it’s not always because it’s confident the market will stay …